Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
IDEXX Laboratories is planning a CEO transition. Jonathan (Jay) Mazelsky will step down as President and Chief Executive Officer on May 12, 2026 and become Executive Chair of the Board until his planned retirement following the annual shareholder meeting in May 2027. Michael (Mike) Erickson, PhD, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO and join the Board as a Class II director on the same date.
Erickson’s CEO terms include a $1,000,000 annual base salary, an annual bonus targeted at 120% of base salary, and a 2026 long‑term equity incentive with a target grant value of at least $7.8 million split between stock options and performance RSUs. His amended change‑in‑control agreement provides cash severance of up to three times salary and average bonus plus benefit continuations and accelerated vesting on time‑based equity after a qualifying change‑in‑control termination. Mazelsky, as Executive Chair, will receive a $1,150,000 base salary and an incentive structure tied to 2026 performance and a time‑vesting RSU grant with a target value of at least $8.275 million.
IDEXX Laboratories entered into Amendment No. 2 to its fourth amended and restated credit agreement, dated November 12, 2025. The amendment adds a three‑year term loan facility and extends the revolving credit facility maturity to five years from the closing date.
The credit arrangement now consists of an unsecured $1.0 billion revolver and an unsecured $250 million term loan, with flexibility to add up to $250 million in incremental revolving commitments and/or term loans. Borrowings may be used for general corporate purposes.
Interest is benchmarked to currencies and tenors selected, with margins tied to the consolidated leverage ratio: for U.S. dollars, base rate or Adjusted Term SOFR/Daily Simple SOFR with margins ranging from 0.0%–1.375%. Comparable benchmarks apply for CAD (PRIMCAN/Term CORRA), EUR (EURIBOR) and AUD (BBSY). Obligations are guaranteed by certain U.S. subsidiaries, with future material U.S. subsidiaries required to guarantee. Covenants include a consolidated leverage ratio and customary negative covenants; events of default are customary, including a change of control.
IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.
Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.
IDEXX Laboratories (IDXX): Director Joseph L. Hooley reported the acquisition of 39 deferred stock units on 10/30/2025 under the company’s Director Deferred Compensation Plan, coded “A.” The filing lists a reference price of $628.54 per share and states the units were issued in exchange for deferred cash compensation of $24,375.00.
Each deferred stock unit represents a contingent right to receive one share of common stock. The units vest immediately upon grant and are payable as common stock following the director’s resignation from the Board or at other nondiscretionary dates allowed by the plan. Following the transaction, 39 shares are beneficially owned directly.
IDEXX Laboratories reported higher third‑quarter results in its Form 10‑Q for the period ended September 30, 2025. Total revenue rose to $1,105,239 thousand from $975,543 thousand a year ago, driven by the Companion Animal Group, where CAG Diagnostics recurring revenue reached $873,273 thousand. Product revenue was $656,159 thousand and service revenue was $449,080 thousand.
Gross profit increased to $683,354 thousand from $596,038 thousand. Net income grew to $274,610 thousand, with diluted EPS of $3.40 compared with $2.80 last year. By category within CAG, IDEXX VetLab consumables were $387,813 thousand, reference laboratory services $362,725 thousand, and CAG Diagnostics capital instruments $51,479 thousand. Water revenue was $54,297 thousand and LPD revenue was $33,944 thousand.
Year‑to‑date operating cash flow was strong at $826,045 thousand. The company repurchased $979,190 thousand of common stock year‑to‑date and ended with cash and cash equivalents of $208,166 thousand. Borrowings under the Credit Facility totaled $455,000 thousand, and total debt (current and long‑term) was $524,822 thousand as of quarter‑end. Shares outstanding were 79,851,330 on October 29, 2025.
IDEXX Laboratories, Inc. announced quarterly results for the period ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details. The information was provided under Item 2.02 of Form 8‑K and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
IDEXX Laboratories (IDXX) filed a Form 3 showing initial beneficial ownership by a reporting person who is a Director. The filing reports 0 shares of Common Stock beneficially owned (Direct) and no derivative securities listed in Table II. The date of the event requiring the statement is 10/06/2025, and the form was filed by one reporting person. The submission is signed by Karen Peacock on 10/14/2025.
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated
Idexx Laboratories insider Form 4: Jonathan Jay Mazelsky, identified as President and CEO and a director, reported a disposal of 1,051 shares of Idexx common stock on 08/15/2025. The form shows 1,051 shares disposed and 82,443.3016 shares beneficially owned following the transaction. The filing was signed by Lily J. Lu as Attorney-in-Fact on 09/04/2025.